保护
Boosting(机器学习)
免疫
免疫学
医学
生物
计算机科学
免疫系统
人工智能
护理部
作者
Archna Singh,Avijit Mazumder,Saumya Das,Anmol Kanda,Pankaj Tyagi,MVNL Chaitanya
出处
期刊:Recent advances in anti-infective drug discovery
[Bentham Science]
日期:2024-06-13
卷期号:20 (1): 5-29
标识
DOI:10.2174/0127724344308638240530065552
摘要
The human microbiome, a diverse microorganism community, crucially defends against pathogens. Probiotics, postbiotics, and paraprobiotics alone and in combination are potent in countering fungal and waterborne infections, particularly against viral threats. This review focuses on the mechanisms of the microbiome against viral infections, emphasizing probiotic interventions. Certain Lactic Acid Bacteria (LAB) strains effectively eliminate toxic aflatoxin B1 (AFB1) from microfungi-produced mycotoxins. LAB binding to AFB1 persists post-gastric digestion, and pre-incubation with mycotoxins reduces probiotic adhesion to mucus. Oral probiotic administration in animals increases mycotoxin excretion, reducing associated health risks. <i>Bifidobacterium longum</i> and <i>Lactobacillus rhamnosus</i> show exceptional efficacy in removing cyanobacterial toxin microcystin-LR from drinking water. Engineered probiotics promise advanced therapeutic applications for metabolic disorders, Alzheimer's, and type 1 diabetes, serving as diagnostic tools for detecting pathogens and inflammation markers. In antimicrobial peptide production, genetically modified probiotics producing human β-defensin 2 (HBD2) treat Crohn's disease with implemented biocontainment strategies preventing unintended environmental impacts.
科研通智能强力驱动
Strongly Powered by AbleSci AI